Clinical Trial Update: Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial compares 24-week versus 48-week treatment with peginterferon alfa-2a plus ribavirin in patients with hepatitis C genotype 1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2009-09-07